Current Clinical Trials
- Sponsor: Sarepta Therapeutics, Inc.
- Recruitment Status: Active
Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy
- Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Recruitment Status: Active, Not Recruiting
Research
Publications
Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion - July 2019
Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D - November 2010
Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins - September 2009
Early adenovirus-mediated gene transfer effectively prevents muscular dystrophy in alpha-sarcoglycan-deficient mice - August 2000
Mouse Models
Several mouse models of sarcoglycan deficiency have been reported; two are cryopreserved at Jackson Laboratories.
B6.129S6-Sgcatm2Kcam/J (stock #008275)
Alpha-sarcoglycan deficiency verified by western blot, RT-PCR analysis and immunofluorescence staining of skeletal muscle. Mice develop progressive muscular dystrophy as early as 6 weeks of age.
B6.Cg-Sgcatm1KamTg(Ckm-SGCE)1Kcam/J (stock #009651)
Homozygous for both α- and ε-sarcoglycan deficiency. These mice have no overt phenotype but have an exaggerated response to mild exercise.
DNA and RNA
Antibodies
Abcam antibodies against alpha-sarcoglycan
- Anti-alpha Sarcoglycan antibody [Ad1/20A6] (ab49451)
- Anti-alpha Sarcoglycan antibody (ab92522)
- Anti-alpha Sarcoglycan antibody (ab130657)
Links on Biocompare to antibodies from 16 different vendors
Links on Antibody Resource to antibodies from 12 different vendors
Other resources
Bioz analyzes, aggregates, and structures data from more than 3.6 million articles and many different resources related to alpha-sarcoglycan can be found on this website.
Help us find a cure.
Your generous donation will help support research to find effective treatments or a cure for LGMD2D.
